Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Hypertensive Black/African American Patients With Type 2 Diabetes
NCT02182830Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and hypertension (HTN) comparing Empagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 weeks. Started Jul 2014; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT02182830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182830.